128 results about "Infective Agent" patented technology

Anti-infective foamable composition and kits include a foamable carrier; a therapeutically safe and effective concentration of an anti-infective agent; an augmenting agent selected from the group consisting of a keratolytic agent and a skin penetration enhancer; and a propellant. The composition is housed in a container and upon release is expandable to form a breakable foam. The foamable carrier is selected to generate a foam of good or excellent quality in the presence of the augmenting agent and anti-infective agent. Methods for treating, alleviating or preventing a disorder of the skin, a body cavity or mucosal surface, wherein the disorder involves a fungal, bacterial or viral infection as one of its etiological factors, is described.

Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.

Devices are provided which are functionalized to include surface regions having anti-infective agents. Methods are provided for functionalizing various material surfaces to include active surface regions for binding anti-infective agents. Methods are provided by which anti-infective moieties or agents are bonded to functionalized surfaces.

Methods for suppressing, killing, and inhibiting pathogenic cells, such as microorganisms associated with a respiratory infection within the respiratory tract of an animal are described. Methods include the step of exposing the pathogenic cells to an effective amount of nitric oxide, such as through inhalation of nitric oxide gas, in combination with traditional respiratory infection agents, such as antibiotics.

<heading lvl="0">Abstract of Disclosure</heading> A method of forming and preserving a bioremodelable, biopolymer scaffold material by subjecting animal tissue, particularly fetal or neo-natal tissue, to chemical and mechanical processing. The process includes, but is not limited t, harvesting the tissue, optionally extracting growth and differentiation factors from the tissue, inactivating infective agents of the tissue, mechanically expressig undesirable components frm the tissue, delipidizing the tissue, washing the tissue, optionally drying the tissue, and optionally cross-linking the tissue not necessarily in the order described. The resulting product, EBM, is characterized by its microbial, fungal, viral and prion inactivated state. EBM is storng, bioremodelable, drapable and does not undergo calicification. EBM supplants previous inventions because of its unique method of preparation and broad applicability in tissue reengineering

The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.

The present invention provides compositions and devices comprising nanostructure networks, and related methods. The compositions may exhibit enhanced interaction between nanostructures, providing improved device performance (e.g., improved conductivity). In some embodiments, the devices are capable of interacting with various species to produce an observable signal from the device. In some cases, the compositions and devices may be useful in the determination of analytes, including—biological analytes (e.g., DNA, ebola virus, other infective agents, etc.), small, organic analytes, and the like. The embodiments described herein may exhibit high sensitivity and specificity to analytes and may be capable of analyte detection at femtomolar concentrations (e.g., 10 fM).

The present disclosure provides a method for enhancing the anti-tumor efficacy of an Fc fusion protein which binds specifically to a target, e.g., a co-inhibitory or co-stimulatory receptor of ligand, on a T cell in a subject afflicted with a cancer or a disease caused by an infectious agent and alters the activity of the immunomodulatory target, thereby potentiating an endogenous immune response against cells of the cancer or the infectious agent, wherein the method comprises selecting, designing or modifying the Fc region of the Fc fusion protein so as to enhance the binding of said Fc region to an activating Fc receptor (FcR). The disclosure also provides an Fc fusion protein produced by said method which has an enhanced ability to potentiate an endogenous immune response against cells of a cancer or an infectious agent in a subject. The disclosure further provides a method for treating a subject which comprises administering to the subject a therapeutically effective amount of an Fc fusion protein, wherein the Fc region of the Fc fusion protein has been selected, designed or modified so as to increase the binding of said Fc region to an activating FcR.

A composition and method are described for sanitizing or otherwise treating a material such as a non-living surface, living tissue, soil or atmosphere which may be contaminated by a toxin, chemical warfare agent, insect, prion, microorganism or other infectious agent. The composition generally includes an aqueous composition mixture that includes: (a) lower alkanol; (b) an alkalinating agent, and (c) a fatty acid salt and/or ester. The components are present in an effective amount to sanitize (or treat) a material (or modifying a chemical contained thereon) to which the composition is applied. Also described are methods of making the composition.

The present invention relates to a method for producing a profile identifying a microorganism based on surface enhanced Raman scattering (SERS) and an apparatus thereof. The method comprises: (1) placing the microorganism on a SERS-active substrate; (2) mounting the microorganism with a mounting solution; (3) obtaining a SERS spectrum of the microorganism in step (2); and (4) analyzing the SERS spectrum to produce the profile.

The present invention also relates to a method for detecting morphology alteration of a microorganism due to an antimicrobial agent or an infectious agent based on SERS and an apparatus thereof. The method comprises: (1) placing the microorganism on a SERS-active substrate; (2) mounting the microorganism with a mounting solution; (3) treating the microorganism with a pharmaceutically effective amount of the antimicrobial agent or the infectious agent; (4) obtaining a SERS spectrum of the microorganism in step (3); and (5) identifying effect of the antimicrobial agent or the infectious agent by at least one new peak in the SERS spectrum in step (4) compared to a SERS spectrum of a control sample, wherein the control sample is not treated with the antimicrobial agent or the infectious agent.

1. The present invention provides compositions and methods for reversibly inhibiting S-adenosyl-L-homocysteine (SAH) hydrolase. The compounds of the present invention can be used as an anti-hemorrhagic viral infection agent, an immunosuppressant, a homocysteine lowering agent, or an anti-neoplasm agent. The compositions and methods of the present invention can be used for the prevention and treatment of hemorrhagic virus infection, autoimmune diseases, autograft rejection, neoplasm, hyperhomocysteineuria, cardiovascular disease, stroke, Alzheimer's disease, multiple sclerosis or diabetes. The compound of the present invention and/or used in the present invention has the formula (I):

Provided are methods of determining a resistance-adjusted dosage regimen of an anti-infective agent for treatment of an infection of a mammal by a resistant infective organism, wherein an effective dosage regimen of the anti-infective agent is known for treatment of an infection of the mammal by a susceptible strain of the infective organism. Methods of treating a cefepime resistant bacterial infection in a patient are also provided.

A vaccine for West Nile virus that protects a subject against West Nile infection comprising an a pharmaceutically acceptable carrier and a therapeutically effective does of an infectious agent selected from the group consisting of: a live attenuated infectious (+) RNA virus designated as WN1415, a vector comprising infectious DNA encoding an infectious (+) RNA molecule encoding the West Nile virus, and the West Nile (+) RNA virus designated as WN956D117B3 (GenBank #M12294).

An apparatus for use in an assay to be conducted upon a fluid sample suspected of containing an analyte of interest, comprises a vessel for receiving a sample, and an element for capturing an analyte of interest. The element is insertable into the vessel for the purposes of the assay, and is coated on at least one surface with a specific binding partner for the analyte of interest. The element further having on a surface remote from the coated surface, structure adapted for manipulating the element for convenient analysis, whereby it is possible to detect and quantify microorganisms, particularly assay for infective agents such as bacteria, and viral particles and prions, or other particles that may be associated with a disease state, especially in humans.